Therapeutic results of benazepril and meglumine adenosine cyclophosphate on congestive heart failure

Objective:To investigate the therapeutic results of benazepril and meglumine adenosine cyclophosphate on congestive heart failure(CHF).Methods:A total of 243 patients were randomly divided into control group(81 cases,accepted routine therapy) and the first treatment group(80 cases,accepted routine therapy and Benazepril),the second treatment group(82 cases,accepted routine therapy and benazepril plus meglumine adenosine cyclophosphate),all treated for 14 days.LVEF(left ventricular ejection fraction)、FS(left ventricular fractional shortening)and CI(cardiac index)by echocardiography and plasma BNP level were evaluated before and after 14 days therapy.Results:After 14 days therapy,compared with control group,the LVEF、FS、CI significantly improved(P0.05 all),BNP level significantly decreased(P0.05)in all treatment groups;compared to the first treatment group the second one had more lower BNP level(P0.05).Conclusion:Benazepril may markedly decline BNP level,and improve patients′ cardiac function,combined with meglumine adenosine cyclophosphate may decline BNP level more for CHF patients.